Healthcare
Terns Pharmaceuticals, Inc.(TERN)
Live Price
Offline$1.20
+0.00% today
1Y Change
-11.11%
Window
Jun 20, 2025 โ Jun 9, 2026
- Market Cap
- $4.77B
- Revenue Growth
- 0.0%
- EPS Growth
- +8.0%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 20, 2025 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Terns Pharmaceuticals, Inc. (TERN) is a Healthcare stock with a market cap of $4.77B and listed on NASDAQ. The stock last traded around $1.20 and down 11.1% across the available one-year price window (Jun 20, 2025 โ Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +8.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +8.0%, free cash flow -17.3% with operating margin 0.0% and ROIC -10.9%. Stock Foundry combines TERN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +8.0%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -10.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +0.0% | -15.6% | โ |
2026 Apr 2, 2026 | +12.1% | -25.0% | -11.1% | -33.3% |
2025 Nov 10, 2025 | +10.0% | -7.4% | -5.3% | +36.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TERN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TERN Max Drawdown
-75.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TERN and SPY.
Company Overview
Terns Pharmaceuticals, Inc.
NASDAQ Global Select
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
- Leadership
- Amy L. Burroughs
- IPO Date
- Feb 5, 2021
- Employees
- 59
- Street Address
- 1065 East Hillsdale Boulevard
- Mailing
- Foster City, CA, 94404
- Region
- Foster City, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 525 5535
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 4.9
Growth
- Revenue
- 0.0%
- EPS
- +8.0%
- Free Cash Flow
- -17.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -20.0%
- ROIC
- -10.9%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 62.41
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.